HCAR2 anticorps (Middle Region)

N° du produit ABIN952597

Cet anticorps Lapin Polyclonal détecte spécifiquement HCAR2 dans WB et EIA. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour HCAR2 anticorps (Middle Region) (ABIN952597)

Antigène: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp HCAR2 est non-conjugé

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Détail du produit anti-HCAR2 anticorps

Épitope: AA 207-236, Middle Region

Specificité: This antibody recognizes Human GRP109A (Center). Other species not tested.

Purification: Protein A column, followed by peptide affinity purification

Immunogène: KLH conjugated synthetic peptide between 207-236 amino acids from the Central region of human GPR109A Genename: NIACR1

Isotype: Ig Fraction

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS containing 0.09 % (W/V) Sodium Azide as preservative

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Détails sur HCAR2

Antigène: HCAR2 (Hydroxycarboxylic Acid Receptor 2 (HCAR2))

Autre désignation: GPR109A

Sujet: NIACR1 acts as a high affinity receptor for both nicotinic acid (also known as niacin) and (D)-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamideSynonyms: G-protein coupled receptor 109A, G-protein coupled receptor HM74A, HM74A, NIACR1, Niacin receptor 1, Nicotinic acid receptor, PUMA-G, Pumag

Poids moléculaire: 41850 Da

ID gène: 338442

NCBI Accession: NP_808219